JW Pharmaceutical has unveiled new preclinical findings and its global development strategy for DDC-02, an investigational therapy for rare neurodevelopmental disorders, at the World Orphan Drug Congress (WODC) USA 2026 held in Boston, Massachusetts.
The company presented data showing that DDC-02 improved cognitive and behavioral function across multiple animal models of rare neurodevelopmental disorders. These included Pitt-Hopkins syndrome (PTHS), Fragile X syndrome (FXS), and Rett syndrome (RTT), three conditions that have different genetic causes but share significant cognitive and behavioral challenges.
The findings attracted attention because DDC-02 demonstrated consistent benefits across all tested disease models, suggesting the therapy may have broad potential in rare neurological disorders.
DDC-02 is an orally administered small-molecule drug candidate discovered by JW Pharmaceutical. The therapy is designed to regulate intracellular signaling pathways involved in brain development and neural circuit function.
According to the preclinical data presented at the conference, DDC-02 restored impaired cognitive and behavioral performance to levels similar to those seen in healthy control animals.
Researchers observed these effects in animal models representing:
Although each disorder is caused by different genetic mutations, DDC-02 produced similar improvements across all models.
The company believes these results indicate that the drug may work by improving synaptic plasticity and supporting healthy neural circuit activity, which are often disrupted in neurodevelopmental disorders.
Restoration of Function Seen Even in Established Disease Models
One of the most notable findings from the research was that DDC-02 restored cognitive and behavioral function even in animals with fully developed disease symptoms.
This observation is important because neurodevelopmental disorders are generally considered difficult to reverse once symptoms have appeared. Many of these conditions begin during early brain development, leading researchers to believe that treatment opportunities may be limited later in life.
However, the results suggest that mature neural circuits may still retain the ability to recover function when targeted appropriately.
According to JW Pharmaceutical, the findings support the possibility that meaningful improvements could be achieved even after disease symptoms have become established.
Pitt-Hopkins Syndrome Selected as Lead Development Program
JW Pharmaceutical plans to advance DDC-02 initially for Pitt-Hopkins syndrome, which will serve as the lead indication for the program.
The company is targeting entry into global multi-regional clinical studies in 2028.
Following development in Pitt-Hopkins syndrome, JW Pharmaceutical intends to expand the program into additional rare neurodevelopmental disorders, including Fragile X syndrome and Rett syndrome.
The strategy reflects the company's belief that DDC-02 may address common neurological deficits found across multiple disorders despite their different genetic origins.
Global Partnership Strategy Presented at WODC USA 2026
In addition to presenting scientific findings, JW Pharmaceutical used the conference to outline its global development and partnering plans.
Throughout the event, company representatives held discussions with pharmaceutical companies, biotechnology firms, and investment groups regarding potential collaborations.
The discussions focused on several opportunities, including:
The company aims to support the future development of DDC-02 through both internal programs and external partnerships.
Company Leadership Highlights Potential of DDC-02
Dr. Sun Young Kim, Executive Head of R&D Strategy at JW Pharmaceutical, said the consistency of the results across multiple disease models was encouraging.
According to Dr. Kim, DDC-02 demonstrated efficacy across neurodevelopmental disorders with different genetic causes, supporting its potential as a broad therapeutic approach.
He also highlighted the finding that cognitive and behavioral functions returned to normal levels in adult disease models, describing the observation as particularly promising for future development.
JW Pharmaceutical believes these findings support further advancement of DDC-02 as a potential treatment option for patients living with rare neurodevelopmental disorders.
Understanding Pitt-Hopkins Syndrome
Pitt-Hopkins syndrome is an ultra-rare neurodevelopmental disorder caused by mutations in the TCF4 gene.
The condition is associated with:
The disorder affects approximately one in every 30,000 to 40,000 people.
Currently, there are no approved disease-modifying therapies for Pitt-Hopkins syndrome. Treatment mainly focuses on symptom management and supportive care.
Fragile X Syndrome Remains a Significant Unmet Need
Fragile X syndrome is the most common inherited cause of intellectual disability and is caused by mutations in the FMR1 gene.
Patients often experience:
The condition affects approximately one in 4,000 males and one in 8,000 females.
Despite ongoing research efforts, no disease-modifying therapies have been approved for Fragile X syndrome.
The global treatment market for Fragile X syndrome was estimated at approximately USD 1.2 billion to USD 2.6 billion in 2024, with continued growth expected as new therapies advance through clinical development.
Rett Syndrome Treatment Landscape Continues to Evolve
Rett syndrome is a rare neurodevelopmental disorder caused primarily by mutations in the MECP2 gene and mainly affects females.
Children with Rett syndrome often experience normal early development before gradually losing language, communication, and motor skills.
Common symptoms include:
The disorder affects approximately one in 10,000 to 15,000 individuals worldwide.
In 2023, the U.S. Food and Drug Administration approved trofinetide (Daybue), the first therapy specifically approved for Rett syndrome.
The annual cost of treatment is estimated to be around USD 375,000 per patient, highlighting both the significant unmet need and the value of effective treatment options in this area.
JW Pharmaceutical Plans Next Steps for DDC-02
Following the encouraging preclinical findings, JW Pharmaceutical is preparing to move DDC-02 toward global clinical development.
The company plans to continue evaluating the therapy's potential across multiple rare neurodevelopmental disorders while pursuing strategic collaborations to support future clinical studies and commercialization efforts.